MUC1 and neoplasm: discovered that humanized TAB004 (hTAB004), targeting transformed MUC1 (tMUC1), shows notable efficacy in treating TNBC by binding and internalizing tMUC1, effectively inhibiting tumor volume growth and improving patient survival (144).